Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 394Multiple Endocrine Neoplasia Type 1 156Carcinoma, Neuroendocrine 123Thyroid Cancer, Papillary 118Pituitary Neoplasms 114Thyroid Neoplasms 100Pheochromocytoma 91Neoplasms 79Carcinoid Tumor 76Thyroid Carcinoma, Anaplastic 73Adrenocortical Carcinoma 73Paraganglioma 65Neoplasm Metastasis 56Adenocarcinoma, Follicular 53Carcinoma, Non-Small-Cell Lung 51Carcinoma, Medullary 50Insulinoma 49Pancreatic Neoplasms 47Adenoma, Islet Cell 47Colorectal Neoplasms 44Breast Neoplasms 44Small Cell Lung Carcinoma 42Sarcoma 42Gastro-enteropancreatic neuroendocrine tumor 42Carcinoma, Renal Cell 41Somatostatinoma 38Head and Neck Neoplasms 38Melanoma 37Lung Neoplasms 37Adrenal Gland Neoplasms 34

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dumping Syndrome × Endocrine × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡